Compare BWXT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWXT | BBIO |
|---|---|---|
| Founded | 1867 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9B | 15.3B |
| IPO Year | 2010 | 2019 |
| Metric | BWXT | BBIO |
|---|---|---|
| Price | $195.79 | $71.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 24 |
| Target Price | ★ $204.60 | $83.00 |
| AVG Volume (30 Days) | 740.8K | ★ 2.8M |
| Earning Date | 05-26-2026 | 05-22-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ 16.61 | N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | ★ $1,687,738,000.00 | $502,076,000.00 |
| Revenue This Year | $18.90 | $88.86 |
| Revenue Next Year | $10.10 | $74.11 |
| P/E Ratio | $54.83 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $84.21 | $28.33 |
| 52 Week High | $220.57 | $84.94 |
| Indicator | BWXT | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 52.30 |
| Support Level | $187.01 | $70.65 |
| Resistance Level | $218.46 | $79.56 |
| Average True Range (ATR) | 9.08 | 3.33 |
| MACD | -1.44 | 0.67 |
| Stochastic Oscillator | 20.98 | 65.78 |
BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.